What risk does the use of intravenous amphetamines present compared to transdermal formulations?

The use of intravenous amphetamines presents a higher risk for addiction compared to transdermal formulations due to the route of administration and the resulting pharmacokinetics. Intravenous administration leads to rapid spikes in drug levels within the bloodstream and reaches the central nervous system more quickly, enhancing the drug's euphoric effects. This fast onset of action increases the potential for misuse and the subsequent risk of developing substance use disorders.

In contrast, transdermal formulations provide a controlled and gradual release of the drug into the bloodstream, leading to more stable drug levels and a lower potential for immediate euphoria. This sustained and steady pharmacological effect reduces the likelihood of addictive behaviors associated with the medication, as users are less likely to experience the intense highs and lows that can accompany more immediate routes of administration.

Thus, the pharmacological properties and abuse potential of intravenous amphetamines significantly contribute to the higher likelihood of addiction when compared to transdermal formulations.